Regeneron expands Sanofi alliance. Regeneron stock trades at EUR 653.35.
Published on 10/04/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 1, 2026, Regeneron Pharmaceuticals, Inc. and Sanofi announced an expanded antibody collaboration involving multiple next-generation, long-acting immunology antibodies, according to the Regeneron investor release. Lang & Schwarz quoted Regeneron stock at EUR 653.35 on October 4, 2026, at 5:12 p.m. CEST, unchanged versus the last Xetra close of EUR 653.35.
Weekend trading at Lang & Schwarz
Regeneron stock was quoted at EUR 653.35 in weekend trading at Lang & Schwarz on October 4, 2026. The bid was EUR 652.70 and the ask was EUR 654.00. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Regeneron stock.
Expanded antibody collaboration
Under the expanded agreement, Regeneron and Sanofi will co-develop and co-commercialize four new long-acting antibodies targeting interleukin-13, an interleukin-4 and interleukin-13 bispecific, interleukin-4 and interleukin-4 receptor alpha. Regeneron will receive an upfront payment of USD 1 billion and may receive up to an additional USD 7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future profits from the potential products equally, according to the company release.
Last Xetra trading day
The last Xetra close at Lang & Schwarz was EUR 653.35 on October 2, 2026. Regeneron’s next Xetra session is scheduled for October 5, 2026.
